New magic bullets can hit more than one target

Bibliography

• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7
   PubMed Web of Science ®Google Scholar
• Presta LG. Selection, design, and engineering of therapeutic antibodies. J Allergy Clin Immunol 2005;116:731-6
   PubMed Web of Science ®Google Scholar
• Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6:343-57
   PubMed Web of Science ®Google Scholar
• Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol 2008;317:103-23
   PubMed Web of Science ®Google Scholar
• Nowakowski A, Wang C, Powers DB, et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA 2002;99:11346-50
   PubMed Web of Science ®Google Scholar
• Garcia-Rodriguez C, Levy R, Arndt JW, et al. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol 2007;25:107-16
   PubMed Web of Science ®Google Scholar
• de KJ, Bakker AB, Marissen WE, et al. A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Ann Rev Med 2007;58:359-68
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-76
   PubMed Web of Science ®Google Scholar
• Stein R, Qu Z, Chen S, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004;10:2868-78
   PubMed Web of Science ®Google Scholar
• Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002;62:200-7
   PubMed Web of Science ®Google Scholar
• Lu D, Zhang H, Koo H, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005;280:19665-72
   PubMed Web of Science ®Google Scholar
• Ford CH, Osborne PA, Rego BG, Mathew A. Bispecific antibody targeting of doxorubicin to carcinoembryonic antigen-expressing colon cancer cell lines in vitro and in vivo. Int J Cancer 2001;92:851-5
   PubMed Web of Science ®Google Scholar
• Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996;39:797-809
   PubMed Web of Science ®Google Scholar
• Lubberts E, Koenders MI, Oppers-Walgreen B, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004;50:650-9
   PubMed Web of Science ®Google Scholar
• Viola A, Luster AD. Chemokines and their receptors: drug targets in immunity and inflammation. Ann Rev Pharmacol Toxicol 2008;48:171-97
   PubMed Web of Science ®Google Scholar
• Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 2005;23:5044-51
   PubMed Web of Science ®Google Scholar
• Leonard JP, Friedberg JW, Younes A, et al. A Phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007;18:1216-23
   PubMed Web of Science ®Google Scholar
• Anti-Rabies Antibody Cocktail. Crucell N.V. CA Leiden The Netherlands 2008. Available from: http://crucell.com/R_and_D-Clinical_Development-Rabies_Antibody_Product [Last accessed 22 May 2008]
   Google Scholar
• Cao Y, Lam L. Bispecific antibody conjugates in therapeutics. Adv Drug Deliv Rev 2003;55:171-97
   PubMed Web of Science ®Google Scholar
• Fischer N, Leger O. Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 2007;74:3-14
   PubMed Web of Science ®Google Scholar
• Suresh MR, Cuello AC, Milstein C. Bispecific monoclonal antibodies from hybrid hybridomas. Methods Enzymol 1986;121:210-28
   PubMed Web of Science ®Google Scholar
• Schlereth B, Quadt C, Dreier T, et al. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother 2006;55:503-14
   PubMed Web of Science ®Google Scholar
• Lu D, Zhang H, Ludwig D, et al. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 2004;279:2856-65
   PubMed Web of Science ®Google Scholar
• Wu C, Ying H, Grinnell C, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007;25:1290-7
   PubMed Web of Science ®Google Scholar
• Robson SC, Lee D, Urbaniak S. Anti-D immunoglobulin in RhD prophylaxis. Br J Obstet Gynaecol 1998;105:129-34
   PubMedGoogle Scholar
• Haurum JS. Recombinant polyclonal antibodies: the next generation of antibody therapeutics? Drug Discov Today 2006;11:655-60
   PubMed Web of Science ®Google Scholar
• Wiberg FC, Rasmussen SK, Frandsen TP, et al. Production of target-specific recombinant human polyclonal antibodies in mammalian cells. Biotechnol Bioeng 2006;94:396-405
   PubMed Web of Science ®Google Scholar
• Reid C, Rushe M, Jarpe M, et al. Structure activity relationships of monocyte chemoattractant proteins in complex with a blocking antibody. Protein Eng Des Sel 2006;19:317-24
   PubMed Web of Science ®Google Scholar
• Ransohoff RM. Natalizumab and PML. Nat Neurosci 2005;8:1275
   PubMed Web of Science ®Google Scholar
• Sheridan C. TeGenero fiasco prompts regulatory rethink. Nat Biotechnol 2006;24:475-6
   PubMed Web of Science ®Google Scholar